The Blue Box Biomedical Solutions
The Blue Box offers a non-invasive, radiation-free breast cancer detection device, providing reliable screening for women aged 20-45.
Founded
2021The Blue Box offers a non-invasive, radiation-free breast cancer detection device, providing reliable screening for women aged 20-45.
The Blue Box Biomedical Solutions was founded with the mission to revolutionize breast cancer detection for women aged 20-45, who often face unreliable screening options. Their vision is to provide a pain-free, low-cost, and radiation-free diagnostic tool that detects breast cancer through urine analysis with an impressive sensitivity of 83%. Set to launch in 2024, The Blue Box will be available in private gynecology clinics through a Diagnostics-as-a-Service subscription model and a pay-per-test revenue stream shared with doctors.
Notable figures associated with The Blue Box include its innovative team of biomedical engineers and healthcare professionals dedicated to improving early cancer detection. The company has garnered attention from key investors in the health tech sector, recognizing its potential to significantly impact women's health. By offering a non-invasive and accurate screening method, The Blue Box aims to reduce the number of undiagnosed breast cancer cases and unnecessary follow-up procedures, thereby enhancing patient outcomes and healthcare efficiency.
Companies similar to The Blue Box Biomedical Solutions include Cellens, Caia, Oncodea and iSono Health.
The Blue Box Biomedical Solutions was founded in 2021.
The Blue Box Biomedical Solutions' headquarters is located in Irvine, CA, US.
The Blue Box Biomedical Solutions' most recent funding round was for €625k (EUR) in October 2023.
As of Oct 31, 2023, The Blue Box Biomedical Solutions has disclosed funding of €1.5M (EUR). Undisclosed round amounts are excluded.
The Blue Box Biomedical Solutions has 6 employees as of Feb 4, 2024.
